NEW YORK - Oramed Pharmaceuticals Inc . (NASDAQ:ORMP), a clinical-stage pharmaceutical company with a market capitalization of $87 million, has announced the formation of a new joint venture, OraTech ...

OraTech to receive royalty payments from sales of oral insulin in China, where a Marketing Authorization Application has been submitted, and commercialization preparations are underway by HTIT. NEW ...

Oramed Pharmaceuticals (NASDAQ:ORMP) formed a JV with Hefei Tianhui Biotech (HTIT), OraTech Pharmaceuticals, which is a strategic initiative to move its assets forward. The JV partners recently made ...

(RTTNews) - Oramed Pharmaceuticals (ORMP) on Tuesday announced a transformative joint venture with Hefei Tianhui Biotech Co., Ltd. (HTIT), launching OraTech Pharmaceuticals Inc. This new company will ...

New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Oramed ...

OraTech will utilize HTIT’s experience in capsule production to establish a scalable supply chain for clinical trials and future commercialization. The company is focused on registering oral insulin ...

OraTech will utilize HTIT's experience in capsule production to establish a scalable supply chain for clinical trials and future commercialization. The company is focused on registering oral insulin ...